Recently, a growing body of evidence has demonstrated that FGF21 may be a promising therapeutic option for treating DCM, particularly in reducing oxidative stress [121], inflammation [121], apoptosis [122], and lipid accumulation [123] in the myocardium. The gene discussed is FGF21; the disease is familial dilated cardiomyopathy.